Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Change in Accured Expenses (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Change in Accured Expenses for 15 consecutive years, with -$1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 120.47% to -$1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$12.5 million, a 1029.58% decrease, with the full-year FY2024 number at -$6.7 million, up 77.54% from a year prior.
  • Change in Accured Expenses was -$1.4 million for Q3 2025 at Usana Health Sciences, down from -$38000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $14.5 million in Q4 2022 to a low of -$29.8 million in Q1 2022.
  • A 5-year average of -$5.7 million and a median of -$4.8 million in 2024 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 432.86% in 2024; the steepest drop was 702.74% in 2024.
  • Usana Health Sciences' Change in Accured Expenses stood at -$13.7 million in 2021, then surged by 205.57% to $14.5 million in 2022, then plummeted by 94.47% to $802000.0 in 2023, then plummeted by 702.74% to -$4.8 million in 2024, then skyrocketed by 71.99% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Change in Accured Expenses are -$1.4 million (Q3 2025), -$38000.0 (Q2 2025), and -$6.3 million (Q1 2025).